Evonile Pharma (500672) Q3 24/25 earnings summary

Executive summary

• Q3 revenue was ₹930.0 million versus ₹845.4 million YoY, while net profit was ₹254.5 million versus ₹265.7 million; 9M net profit was ₹716.0 million versus ₹705.1 million.

Financial highlights

• Q3 total income was ₹1,036.0 million versus ₹1,065.0 million YoY; 9M total income was ₹3,037.2 million versus ₹3,350.7 million.

• Q3 profit before tax was ₹352.9 million versus ₹413.1 million YoY; 9M profit before tax was ₹965.3 million versus ₹1,015.1 million.

• Q3 profit after tax was ₹254.5 million versus ₹265.7 million YoY; 9M profit after tax was ₹716.0 million versus ₹705.1 million.

Segment performance

• Operations comprise one business segment: Pharmaceuticals Business.